, Volume 13, Issue 10–11, pp 698–702

État des lieux et mise à jour des traitements systémiques adjuvants

  • Thomas Bachelot
  • Kamel Bouzid
  • Thierry Delozier
  • Alain Lortholary
  • Thierry Petit
Veille Bibliographique / Literature Monitoring


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Albain KS, Paik S, van’t Veer L (2009) Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 18(Suppl 3): S141–S145PubMedCrossRefGoogle Scholar
  2. 2.
    Balakrishnan A, Haysom SA, Ravichandran D (2011) Adjuvant! Online does not significantly influence adjuvant chemotherapy decisions of a breast cancer multidisciplinary team (MDT): a prospective study. Ann Oncol 22(6): 1461–1462PubMedCrossRefGoogle Scholar
  3. 3.
    BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al. (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361(8): 766–776PubMedCrossRefGoogle Scholar
  4. 4.
    Campbell HE, Gray AM, Harris AL, et al. (2010) Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer 103: 776–786; doi:10.1038/sj.bjc.6605863PubMedCrossRefGoogle Scholar
  5. 5.
    Campbell HE, Taylor MA, Harris AL, Gray AM (2009) An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom. Br J Cancer 101(7): 1074–1084PubMedCrossRefGoogle Scholar
  6. 6.
    (2005) « Cancers du sein » Recommandations pour la pratique clinique de Saint-Paul-de-Vence. Oncologie 7: 342–379Google Scholar
  7. 7.
    (2007) « Cancers du sein » Recommandations pour la pratique clinique de Saint-Paul-de-Vence. Oncologie 9: 593–644Google Scholar
  8. 8.
    Coleman RE, Thorpe HC, Cameron D, et al. (2010) Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04). SABCS, abs S4–S5Google Scholar
  9. 9.
    Colleoni M, Giobbie-Hurder A, Regan MM, et al. (2011) Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29(9): 1117–1124PubMedCrossRefGoogle Scholar
  10. 10.
    Cuzick J, Sestak I, Baum M, et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12): 1135–1141PubMedCrossRefGoogle Scholar
  11. 11.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687–717CrossRefGoogle Scholar
  12. 12.
    Eiermann W, Pienkowski T, Crown J, et al. (2008) BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC T) in women with HER2/neu negative axillary lymph node positive early breast cancer. SABCS, abs 77Google Scholar
  13. 13.
    Ellis P, Barrett-Lee P, Johnson L, et al. (2009) Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomized controlled trial. Lancet 373(9676): 1681–1692PubMedCrossRefGoogle Scholar
  14. 14.
    Fisher B, Jeong JH, Dignam J, et al. (2001) Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr (30): 62–66PubMedGoogle Scholar
  15. 15.
    Fisher ER, Redmond C, Fisher B, Bass G (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP). Prognostic discriminants for 8-year survival for node-negative invasive breast cancer patients. Cancer 65(9 Suppl): 2121–2128PubMedCrossRefGoogle Scholar
  16. 16.
    Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20): 1938–1948PubMedCrossRefGoogle Scholar
  17. 17.
    Francis P, Crown J, Di Leo A, et al. (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100(2): 121–133PubMedCrossRefGoogle Scholar
  18. 18.
    Gnant M, Mlineritsch B, Schippinger W, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7): 679–691PubMedCrossRefGoogle Scholar
  19. 19.
    Gnant M, Mlineritsch B, Stoeger H, et al. (2010) Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. J Clin Oncol 28: 15s, (Suppl; abstr 533)CrossRefGoogle Scholar
  20. 20.
    Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. (2009) High-risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27(34): 5700–5706PubMedCrossRefGoogle Scholar
  21. 21.
    Goss PE, Ingle JN, Chapman JAW, et al. (2010) Final Analysis of NCIC CTG MA.27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. SABCS, ab S1-1Google Scholar
  22. 22.
    Goss PE, Muss HB, Ingle JN, et al. (2008) Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin Breast Cancer 8(5): 411–417PubMedCrossRefGoogle Scholar
  23. 23.
    Hackshaw A, Baum M, Fornander T, et al. (2009) Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst 101(5): 341–349PubMedCrossRefGoogle Scholar
  24. 24.
    Halyard MY, Pisansky TM, Dueck AC, et al. (2009) Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 27(16): 2638–2644PubMedCrossRefGoogle Scholar
  25. 25.
    Héry M, Delozier T, Ramaioli A, et al. (2002) Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse? Breast 11(5): 442–448PubMedCrossRefGoogle Scholar
  26. 26.
    Jones S, Holmes FA, O’shaughnessy J, et al. (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol 27(8): 1177–1183PubMedCrossRefGoogle Scholar
  27. 27.
    Martín M, Seguí MA, Antón A, et al. (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23): 2200–2210PubMedCrossRefGoogle Scholar
  28. 28.
    Mook S, Schmidt MK, Rutgers EJ, et al. (2009) Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. Lancet Oncol 10(11): 1070–1076PubMedCrossRefGoogle Scholar
  29. 29.
    Olivotto IA, Bajdik CD, Ravdin PM, et al. (2005) Population-based validation of the prognostic model Adjuvant! for early breast cancer. J Clin Oncol 23(12): 2716–2725PubMedCrossRefGoogle Scholar
  30. 30.
    Paridaens RJ, Gelber S, Cole BF, et al. (2010) Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat 123(1): 303–310PubMedCrossRefGoogle Scholar
  31. 31.
    Park YH, Kim ST, Cho EY, et al. (2010) A risk stratification by hormonal receptors (ER, PgR) and HER2 status in small (⩽ 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 119(3): 653–661PubMedCrossRefGoogle Scholar
  32. 32.
    Penault-Llorca F, André F, Sagan C, et al. (2009) Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(17): 2809–2815PubMedCrossRefGoogle Scholar
  33. 33.
    Perez EA, Suman VJ, Davidson NE, et al. (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8): 1231–1238PubMedCrossRefGoogle Scholar
  34. 34.
    Perez EA, Suman VJ, Davidson NE, et al. (2009) Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER-positive adjuvant breast cancer trial. SABCS, abs 80Google Scholar
  35. 35.
    Shulman LN, Cirrincione C, Berry DA, et al. (2010) Four versus 6 cycles of doxorubicin and cyclophosphamide (AC) or paclitaxel (T) as adjuvant therapy for breast cancer in women with 0–3 positive axillary nodes: CALGB 40101 − A 2 × 2 factorial phase III trial: first results comparing 4 versus 6 cycles of therapy. SABCS, abs S66-S3Google Scholar
  36. 36.
    Slamon D, Eiermann W, Robert N, et al. (2009) Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 neu positive early breast cancer patients: BCIRG 006 Study. SABCS, abs 62Google Scholar
  37. 37.
    Swain SM, Jeong JH, Geyer CE Jr, et al. (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362(22): 2053–2065PubMedCrossRefGoogle Scholar
  38. 38.
    van de Velde CJ, Rea D, Seynaeve C, et al. (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase III trial. Lancet 377(9762): 321–331PubMedCrossRefGoogle Scholar
  39. 39.
    Verma S, Lavasani S, Mackey J, et al. (2010) Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol 17(4): 20–33PubMedCrossRefGoogle Scholar
  40. 40.
    Viale G, Regan MM, Dell’orto P, et al. (2011) Which patients benefit most from adjuvant aromatase inhibitors Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol 22(10): 2201–2207PubMedCrossRefGoogle Scholar
  41. 41.
    Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17(4): R245–R262PubMedCrossRefGoogle Scholar
  42. 42.
    Yerushalmi R, Woods R, Ravdin PM, et al. (2010) Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11(2): 174–183PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2011

Authors and Affiliations

  • Thomas Bachelot
  • Kamel Bouzid
  • Thierry Delozier
  • Alain Lortholary
  • Thierry Petit

There are no affiliations available

Personalised recommendations